Braveheart Bio Inc. (BRVE:NASDAQ) closed at $21.82 on October 27, 2026, down 0.23% on the day. The stock trades 31.8% below its 52-week high of $32.00 and 22.2% above its 52-week low of $17.86. Over the past year, it lost 26.6%. Braveheart Bio Inc. is part of the Health Care sector.
In 57 trading sessions since August 7, 2026, BRVE closed higher on 32 days (56%). Its best day was September 8, 2026 (+9.99%) and its worst was September 21, 2026 (-14.32%). The stock moved 10% or more in a single session 2 times.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.
Find more stocks like BRVE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.